Original Article

You have full text access to this OnlineOpen article

A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia

  1. Mark A. Weiss M.D.1,
  2. Timothy B. Aliff M.D.1,‡,*,
  3. Martin S. Tallman M.D.2,
  4. Stanley R. Frankel M.D.3,†,
  5. Matt E. Kalaycio M.D.4,
  6. Peter G. Maslak M.D.1,
  7. Joseph G. Jurcic M.D.1,
  8. David A. Scheinberg M.D., Ph.D.1,
  9. Todd E. Roma B.S.1

Article first published online: 23 JUL 2002

DOI: 10.1002/cncr.10707

Issue

Cancer

Cancer

Volume 95, Issue 3, pages 581–587, 1 August 2002

Additional Information

How to Cite

Weiss, M. A., Aliff, T. B., Tallman, M. S., Frankel, S. R., Kalaycio, M. E., Maslak, P. G., Jurcic, J. G., Scheinberg, D. A. and Roma, T. E. (2002), A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer, 95: 581–587. doi: 10.1002/cncr.10707

Author Information

  1. 1

    Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

  2. 2

    Northwestern University Medical School, Chicago, Illinois

  3. 3

    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC

  4. 4

    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio

  1. †

    Genta Incorporated, Two Connell Drive, Berkeley Heights, NJ 07922

  1. ‡

    Fax: (212) 772-8441

*Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021

Publication History

  1. Issue published online: 23 JUL 2002
  2. Article first published online: 23 JUL 2002
  3. Manuscript Accepted: 7 MAR 2002
  4. Manuscript Revised: 26 FEB 2002
  5. Manuscript Received: 3 DEC 2001

Funded by

  • Pharmacia and Upjohn
  • Amgen, Inc.
  • NIH. Grant Number: -5-T32-CA-09207-24

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (79K)

REFERENCES

  • 1
    Rivera GK, Pinkel D, Simone JV, Hancock ML, Crist WM. Treatment of acute lymphoblastic leukemia. Thirty years' experience at St. Jude Children's Research Hospital. N Engl J Med. 1993; 329: 1289–1295.
  • 2
    Hoelzer D. Acute lymphoblastic leukemia—progress in children, less in adults. N Engl J Med. 1993; 329: 1343–1344.
  • 3
    Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood. 1995; 85: 2025–2037.
  • 4
    Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000; 18: 547–561.
  • 5
    Schauer P, Arlin ZA, Mertelsmann R, et al. Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. J Clin Oncol. 1983; 1: 462–470.
  • 6
    Hussein KK, Dahlberg S, Head D, et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood. 1989; 73: 57–63.
  • 7
    Woodruff R, Lister T, Paxton A, Whitehouse J, Malpas J. Combination chemotherapy for hematologic relapse in adult acute lymphoblastic leukemia (ALL). Am J Hematol. 1978; 4: 173–177.
    Direct Link:
  • 8
    Miyawaki S, Mizoguchi H, Tomonaga M, et al. A Phase II study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia. Gan To Kagaku Ryoho. 1998; 25: 2229–2242.
  • 9
    Weiss MA, Drullinsky P, Maslak P, Scheinberg D, Golde DW. A Phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia. 1998; 12: 865–868.
  • 10
    Testi AM, Moleti ML, Giona F, et al. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University “La Sapienza” of Rome. Haematologica. 1997; 82: 664–667.
  • 11
    Lejeune C, Tubiana N, Gastaut JA, et al. High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. Eur J Haematol. 1990; 44: 240–243.
    Direct Link:
  • 12
    Giona F, Testi AM, Amadori S, et al. Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia. Ann Oncol. 1990; 1: 51–55.
  • 13
    Hiddemann W, Buchner T, Heil G, et al. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia. 1990; 4: 637–640.
  • 14
    Wells RJ, Feusner J, Devney R, et al. Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia. J Clin Oncol. 1985; 3: 998–1004.
  • 15
    Arlin ZA, Feldman E, Kempin S, et al. Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults. Blood. 1988; 72: 433–435.
  • 16
    National Cancer Institute, Division of Cancer Treatment. Common toxicity criteria. Bethesda: National Cancer Institute, 1988.
  • 17
    Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood. 1999; 93: 3983–3993.
  • 18
    Scheinberg DA, Maslak P, Weiss M. Acute leukemias. In: DeVitaVT, HellmanS, RosenbergSA, editors. Cancer principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001: 2404–2433.
  • 19
    Heerema NA, Sather HN, Sensel MG, et al. Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group. J Clin Oncol. 1998; 16: 1270–1278.
  • 20
    Weiss M, Maslak P, Feldman E, et al. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol. 1996; 14: 2480–2485.
  • 21
    Doney K, Fisher LD, Appelbaum FR, et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant. 1991; 7: 453–459.
  • 22
    Rosen PJ, Rankin C, Head DR, et al. A Phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia. Leuk Res. 2000; 24: 183–187.
  • 23
    Aguayo A, Cortes J, Thomas D, Pierce S, Keating M, Kantarjian H. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer. 1999; 86: 1203–1209.
    Direct Link:
  • 24
    Esterhay RJ Jr., Wiernik PH, Grove WR, Markus SD, Wesley MN. Moderate dose methotrexate, vincristine, asparaginase, and dexamethasone for treatment of adult acute lymphocytic leukemia. Blood. 1982; 59: 334–345.
  • 25
    Giona F, Annino L, Rondelli R, et al. Treatment of adults with acute lymphoblastic leukemia in first bone marrow relapse: Results of the ALL R-87 protocol. Br J Hematol. 1997; 97: 869–903.
    Direct Link:
  • 26
    Koller CA, Kantarjian HM, Thomas D, et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia. 1997; 11: 2039–2044.
  • 27
    Paciucci PA, Keaveney C, Cuttner J, Holland JF. Mitoxantrone, vincristine, and prednisone in adults with relapsed or primarily refractory acute lymphocytic leukemia and terminal deoxynucleotidyl transferase positive blastic phase chronic myelocytic leukemia. Cancer Res. 1987; 47: 5234–5237.
  • 28
    Pavlovsky S, Muriel FS, Eppinger-Helft M, et al. Daunorubicin, vincristine, and prednisone for remission induction in patients with acute lymphoblastic leukemia in relapse. Cancer Treat Rep. 1983; 67: 425–427.
  • 29
    Kantarjian HM, Walters RS, Keating MJ, Barlogie B, McCredie KB, Freireich EJ. Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia. Cancer. 1989; 64: 16–22.
    Direct Link:
  • 30
    Swain S, Whaley F, Gerber M, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997; 15: 1318–1332.
  • 31
    Dorr RT, Lagel K, McLean S. Cardioprotection of rat heart myocytes with amifostine (Ethyol®) and its free thiol WR-1065, in vitro. Eur J Cancer. 1996; 32A: S21–S25.
View Full Article (HTML) Get PDF (79K)